blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2922534

EP2922534 - METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  12.02.2021
Database last updated on 02.09.2024
FormerThe patent has been granted
Status updated on  06.03.2020
FormerGrant of patent is intended
Status updated on  13.11.2019
FormerExamination is in progress
Status updated on  27.04.2018
Most recent event   Tooltip15.07.2022Lapse of the patent in a contracting state
New state(s): BE		published on 17.08.2022  [2022/33]
Applicant(s)For all designated states
Golden Biotechnology Corporation
101 Hudson Street Suite 2100
Jersey City NJ 07302 / US
[2015/40]
Inventor(s)01 / LIU, Sheng-yung
15f No. 27-6
Sec. 2 Jhong-Jheng E. Road
Danshuei
New Taipei City 251 / TW
02 / WEN, Wu-Che
15f No. 27-6
Sec. 2 Jhong-jheng E. Road
Danshuei
New Taipei City 251 / TW
03 / CHEN, Chih-Ming
15f No. 27-6
Sec. 2 Jhong-jheng E. Road
Danshuei
New Taipei City 251 / TW
 [2015/40]
Representative(s)Wichmann, Hendrik
Wuesthoff & Wuesthoff
Patentanwälte und Rechtsanwalt PartG mbB
Schweigerstraße 2
81541 München / DE
[N/P]
Former [2015/40]Wichmann, Hendrik
Wuesthoff & Wuesthoff
Patentanwälte PartG mbB
Schweigerstraße 2
81541 München / DE
Application number, filing date13857519.618.11.2013
[2015/40]
WO2013US70625
Priority number, dateUS201261729295P21.11.2012         Original published format: US 201261729295 P
[2015/40]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014081675
Date:30.05.2014
Language:EN
[2014/22]
Type: A1 Application with search report 
No.:EP2922534
Date:30.09.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 30.05.2014 takes the place of the publication of the European patent application.
[2015/40]
Type: B1 Patent specification 
No.:EP2922534
Date:08.04.2020
Language:EN
[2020/15]
Search report(s)International search report - published on:US30.05.2014
(Supplementary) European search report - dispatched on:EP11.04.2016
ClassificationIPC:A61K31/122, A61P25/28, A61K36/07, A61P25/00, A61P25/16
[2016/19]
CPC:
A61K31/122 (EP,US); A61K36/07 (EP,US); A61P21/02 (EP);
A61P25/00 (EP); A61P25/16 (EP); A61P25/28 (EP);
A61P9/10 (EP) (-)
Former IPC [2015/40]A61K31/12, A61K31/122, A61P25/28
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/40]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERFAHREN UND ZUSAMMENSETZUNGEN ZUR BEHANDLUNG NEURODEGENERATIVER ERKRANKUNGEN[2015/40]
English:METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES[2015/40]
French:MÉTHODES ET COMPOSITIONS POUR LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES[2015/40]
Entry into regional phase09.06.2015National basic fee paid 
09.06.2015Search fee paid 
09.06.2015Designation fee(s) paid 
09.06.2015Examination fee paid 
Examination procedure09.06.2015Examination requested  [2015/40]
28.10.2016Amendment by applicant (claims and/or description)
26.04.2018Despatch of a communication from the examining division (Time limit: M04)
05.09.2018Reply to a communication from the examining division
12.04.2019Despatch of a communication from the examining division (Time limit: M04)
08.08.2019Reply to a communication from the examining division
14.11.2019Communication of intention to grant the patent
28.02.2020Fee for grant paid
28.02.2020Fee for publishing/printing paid
28.02.2020Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  26.04.2018
Opposition(s)12.01.2021No opposition filed within time limit [2021/11]
Fees paidRenewal fee
19.11.2015Renewal fee patent year 03
10.11.2016Renewal fee patent year 04
13.11.2017Renewal fee patent year 05
14.11.2018Renewal fee patent year 06
14.11.2019Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU18.11.2013
AL08.04.2020
AT08.04.2020
CY08.04.2020
CZ08.04.2020
DK08.04.2020
EE08.04.2020
FI08.04.2020
HR08.04.2020
LT08.04.2020
LV08.04.2020
MC08.04.2020
MK08.04.2020
MT08.04.2020
PL08.04.2020
RO08.04.2020
RS08.04.2020
SI08.04.2020
SK08.04.2020
SM08.04.2020
TR08.04.2020
BG08.07.2020
NO08.07.2020
GR09.07.2020
IS08.08.2020
PT17.08.2020
IE18.11.2020
LU18.11.2020
BE30.11.2020
[2022/33]
Former [2022/32]HU18.11.2013
AL08.04.2020
AT08.04.2020
CY08.04.2020
CZ08.04.2020
DK08.04.2020
EE08.04.2020
FI08.04.2020
HR08.04.2020
LT08.04.2020
LV08.04.2020
MC08.04.2020
MK08.04.2020
MT08.04.2020
PL08.04.2020
RO08.04.2020
RS08.04.2020
SI08.04.2020
SK08.04.2020
SM08.04.2020
TR08.04.2020
BG08.07.2020
NO08.07.2020
GR09.07.2020
IS08.08.2020
PT17.08.2020
IE18.11.2020
LU18.11.2020
Former [2022/27]HU18.11.2013
AL08.04.2020
AT08.04.2020
CY08.04.2020
CZ08.04.2020
DK08.04.2020
EE08.04.2020
FI08.04.2020
HR08.04.2020
LT08.04.2020
LV08.04.2020
MC08.04.2020
MT08.04.2020
PL08.04.2020
RO08.04.2020
RS08.04.2020
SI08.04.2020
SK08.04.2020
SM08.04.2020
TR08.04.2020
BG08.07.2020
NO08.07.2020
GR09.07.2020
IS08.08.2020
PT17.08.2020
IE18.11.2020
LU18.11.2020
Former [2022/26]AL08.04.2020
AT08.04.2020
CZ08.04.2020
DK08.04.2020
EE08.04.2020
FI08.04.2020
HR08.04.2020
LT08.04.2020
LV08.04.2020
MC08.04.2020
PL08.04.2020
RO08.04.2020
RS08.04.2020
SI08.04.2020
SK08.04.2020
SM08.04.2020
TR08.04.2020
BG08.07.2020
NO08.07.2020
GR09.07.2020
IS08.08.2020
PT17.08.2020
IE18.11.2020
LU18.11.2020
Former [2021/46]AL08.04.2020
AT08.04.2020
CZ08.04.2020
DK08.04.2020
EE08.04.2020
FI08.04.2020
HR08.04.2020
LT08.04.2020
LV08.04.2020
MC08.04.2020
PL08.04.2020
RO08.04.2020
RS08.04.2020
SI08.04.2020
SK08.04.2020
SM08.04.2020
BG08.07.2020
NO08.07.2020
GR09.07.2020
IS08.08.2020
PT17.08.2020
IE18.11.2020
LU18.11.2020
Former [2021/33]AL08.04.2020
AT08.04.2020
CZ08.04.2020
DK08.04.2020
EE08.04.2020
FI08.04.2020
HR08.04.2020
LT08.04.2020
LV08.04.2020
MC08.04.2020
PL08.04.2020
RO08.04.2020
RS08.04.2020
SI08.04.2020
SK08.04.2020
SM08.04.2020
BG08.07.2020
NO08.07.2020
GR09.07.2020
IS08.08.2020
PT17.08.2020
LU18.11.2020
Former [2021/31]AL08.04.2020
AT08.04.2020
CZ08.04.2020
DK08.04.2020
EE08.04.2020
FI08.04.2020
HR08.04.2020
LT08.04.2020
LV08.04.2020
MC08.04.2020
PL08.04.2020
RO08.04.2020
RS08.04.2020
SI08.04.2020
SK08.04.2020
SM08.04.2020
BG08.07.2020
NO08.07.2020
GR09.07.2020
IS08.08.2020
PT17.08.2020
Former [2021/24]AL08.04.2020
AT08.04.2020
CZ08.04.2020
DK08.04.2020
EE08.04.2020
FI08.04.2020
HR08.04.2020
LT08.04.2020
LV08.04.2020
PL08.04.2020
RO08.04.2020
RS08.04.2020
SI08.04.2020
SK08.04.2020
SM08.04.2020
BG08.07.2020
NO08.07.2020
GR09.07.2020
IS08.08.2020
PT17.08.2020
Former [2021/10]AL08.04.2020
AT08.04.2020
CZ08.04.2020
DK08.04.2020
EE08.04.2020
FI08.04.2020
HR08.04.2020
LT08.04.2020
LV08.04.2020
PL08.04.2020
RO08.04.2020
RS08.04.2020
SK08.04.2020
SM08.04.2020
BG08.07.2020
NO08.07.2020
GR09.07.2020
IS08.08.2020
PT17.08.2020
Former [2021/09]AL08.04.2020
AT08.04.2020
CZ08.04.2020
DK08.04.2020
EE08.04.2020
FI08.04.2020
HR08.04.2020
LT08.04.2020
LV08.04.2020
RO08.04.2020
RS08.04.2020
SM08.04.2020
BG08.07.2020
NO08.07.2020
GR09.07.2020
IS08.08.2020
PT17.08.2020
Former [2021/08]AL08.04.2020
DK08.04.2020
FI08.04.2020
HR08.04.2020
LT08.04.2020
LV08.04.2020
RO08.04.2020
RS08.04.2020
SM08.04.2020
BG08.07.2020
NO08.07.2020
GR09.07.2020
IS08.08.2020
PT17.08.2020
Former [2021/04]AL08.04.2020
FI08.04.2020
HR08.04.2020
LT08.04.2020
LV08.04.2020
RS08.04.2020
BG08.07.2020
NO08.07.2020
GR09.07.2020
IS08.08.2020
PT17.08.2020
Former [2021/01]FI08.04.2020
HR08.04.2020
LT08.04.2020
LV08.04.2020
RS08.04.2020
BG08.07.2020
NO08.07.2020
GR09.07.2020
IS08.08.2020
PT17.08.2020
Former [2020/51]FI08.04.2020
HR08.04.2020
LT08.04.2020
LV08.04.2020
RS08.04.2020
NO08.07.2020
GR09.07.2020
IS08.08.2020
PT17.08.2020
Former [2020/50]FI08.04.2020
HR08.04.2020
LT08.04.2020
LV08.04.2020
NO08.07.2020
GR09.07.2020
IS08.08.2020
PT17.08.2020
Former [2020/48]FI08.04.2020
LT08.04.2020
NO08.07.2020
IS08.08.2020
PT17.08.2020
Former [2020/47]LT08.04.2020
NO08.07.2020
IS08.08.2020
Former [2020/46]IS08.08.2020
Documents cited:Search[A]US2012071426  (LIU SHENG-YUNG [TW], et al) [A] 1-15* the whole document *;
 [XP]WO2013148701  (GOLDEN BIOTECHNOLOGY CORP [US], et al) [XP] 1-3,7-15 * claims 4, 18-31 *;
 [XI]  - CHI-HUANG CHANG ET AL, "Antrodia cinnamomea Exhibits a Potent Neuroprotective Effect in the PC12 Cell-A[beta]25-35 Model - Pharmacologically through Adenosine Receptors and Mitochondrial Pathway", PLANTA MEDICA, DE, (20121011), vol. 78, no. 17, doi:10.1055/s-0032-1315397, ISSN 0032-0943, pages 1813 - 1823, XP055259856 [X] 1-6,8-15 * abstract * * page 1813, column left, line 1 - line 6 * * page 1814, column left, line 17 - line 27 * * page 1816, column left, paragraph last * * page 1820, column left, lines 15-19, 34-47 * * page 1820, column left, line 58 - column right, line 3 * * page 1822, column left, line 3 - line 10 * [I] 7

DOI:   http://dx.doi.org/10.1055/s-0032-1315397
 [X]  - LI-CHUN WANG ET AL, "In vitro and in vivo comparisons of the effects of the fruiting body and mycelium ofagainst amyloid Î-protein-induced neurotoxicity and memory impairment", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, SPRINGER, BERLIN, DE, (20120221), vol. 94, no. 6, doi:10.1007/S00253-012-3941-3, ISSN 1432-0614, pages 1505 - 1519, XP035060664 [X] 1-15 * abstract * * page 1507, column left, line 9 - line 15 * * page 1508, column left, line 1 - line 5 * * page 1509, column left, line 31 - line 39 * * page 1514, column right, lines 1, 2, 24-43 * * page 1517, column left, line 24 - line 27 * * page 1517, column right, line 33 - line 36 * * page 1518, line 4 - line 22 *

DOI:   http://dx.doi.org/10.1007/s00253-012-3941-3
 [X]  - LIU ET AL, "Comparative anti-inflammatory characterization of wild fruiting body, liquid-state fermentation, and solid-state culture of Taiwanofungus camphoratus in microglia and the mechanism of its action", JOURNAL OF ETHNOPHARMACOLOGY, ELSEVIER IRELAND LTD, IE, (20070721), vol. 113, no. 1, doi:10.1016/J.JEP.2007.03.037, ISSN 0378-8741, pages 45 - 53, XP022162816 [X] 1,2,8-15 * abstract * * page 46, column right, paragraph 2.2 *

DOI:   http://dx.doi.org/10.1016/j.jep.2007.03.037
International search[A]WO0047199  (MEIJI MILK PROD CO LTD [JP], et al);
 [A]US2009036542  (LUU BANG [FR], et al);
 [YP]US2013225691  (LIU SHENG-YUNG [TW], et al)
by applicantUS3598122
 US3598123
 US3710795
 US3731683
 US3742951
 US3814097
 US3921636
 US3972995
 US3993072
 US3993073
 US3996934
 US4031893
 US4031894
 US4060084
 US4069307
 US4077407
 US4201211
 US4230105
 US4292299
 US4292303
 US4476116
 US5116817
 US5336168
 US5358489
 US5540664
 US5665071
 US5665378
 US5695472
 US5837280
 US5869090
 US6391452
 US6923983
 US6929801
 US6946144
 WO2005087297
 US2012071426
 WO2013148701
    - CHI-HUANG CHANG et al., "Antrodia cinnamomea Exhibits a Potent Neuroprotective Effect in the PC12 Cell-Ap 25-35 Model - Pharmacologically through Adenosine Receptors and Mitochondrial Pathway", Planta Med, (20120000), vol. 78, no. 17, doi:doi:10.1055/s-0032-1315397, pages 1813 - 1823, XP055259856

DOI:   http://dx.doi.org/10.1055/s-0032-1315397
    - LI-CHUN WANG et al., "In vitro and in vivo comparisons of the effects of the fruiting body and mycelium of Antrodia camphorata against amyloid β-protein-induced neurotoxicity and memory impairment", Appl Microbiol Biotechnol, (20120000), vol. 94, page 1505
    - LIU et al., "Comparative anti-inflammatory characterization of wild fruiting body, liquid-state fermentation, and solid-state culture of Taiwanofungus camphoratus in microglia and the mechanism of its action", Journal of Ethnopharmacology, (20070815), vol. 113, no. 1, doi:doi:10.1016/j.jep.2007.03.037, pages 45 - 53, XP022162816

DOI:   http://dx.doi.org/10.1016/j.jep.2007.03.037
    - "Methodologies for the Culture and Experimental Use of the PC12 Rat Pheochromocytoma Cell Line", GREENE et al., Culturing Nerve Cells G, MIT Press, (19990000), pages 161 - 187
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.